Document is current
Any future updates will be listed below
-
Authors
Kamps, Suzie https://orcid.org/0009-0009-4264-3040
Habraken, Esmé H. J.
van Amerongen, Suzan
van Paassen, Dirk N.
de Boer, Sterre C. M.
Coomans, Emma M.
Sikkes, Sietske A. M.
Scheltens, Philip
Ossenkoppele, Rik
Vijverberg, Everard G. B.
-
Funding
Funding for this research was provided by:
Zon-MW Off Road (451 001 010)
- License Information
-
More Information
Article History
Received: 30 January 2026
Accepted: 15 June 2026
First Online: 29 July 2026
Declarations
Ethics approval and consent to participate: Written consent forms were obtained from all participants. The NEwTON study is approved by the local ethical committee of the Amsterdam UMC (METc number 2021.011). Consent was obtained according to the Declaration of Helsinki.
Consent for publication: Not applicable.
Competing interests: SK, EHJH, SvA, SCMB, DNvP, and EMC report no competing interests. EGBV has received consultancy fees (paid to the university) for New Amsterdam Pharma, Treeway, ReMynd, Vivoryon, Biogen, Vigil Neuroscience, ImmunoBrain Checkpoint, Muna Therapeutics, Esai, Eli Lilly, CogRX, Therini, UCB and Roche.Within his university affiliation he is PI of studies of DIAN, AC immune, Alnylam, CogRX therapeutics, New Amsterdam Pharma, Janssen, UCB, Roche, Vivoryon, ImmunoBrain, GSK, MSD, Biogen, Alector, Eli Lilly, AriBio Fuij Film Toyama, GemVax. EGBV is co-founder van het CANDIDATE Center Amsterdam UMC. EGBV collaborates on scientific projects with the Dutch Soccer Association (KNVB). RO is currently a full-time employee of Eli Lilly and Company. His contribution to the work presented in this manuscript was performed as an employee of Amsterdam University Medical Centers. RO has received research funding/support from European Research Council, ZonMw, NWO, National Institute of Health, Alzheimer Association, Alzheimer Nederland, Stichting Dioraphte, Cure Alzheimer’s fund, Health Holland, ERA PerMed, Alzheimerfonden, Hjarnfonden, Avid Radiopharmaceuticals, Janssen Research & Development, Roche, Quanterix and Optina Diagnostics, has given lectures in symposia sponsored by GE Healthcare, received speaker fees from Springer, and was an advisory board/steering committee member for Asceneuron, Biogen, Johnson & Johnson and Bristol Myers Squibb. All the aforementioned has been paid to Amsterdam University Medical Centers. SAMS receives grant support from Zon-MW Off Road, grant 451 001 010.
